Multiparametric quantitative phase imaging for real-time, single cell, drug screening in breast cancer.

Abstract

Quantitative phase imaging (QPI) measures the growth rate of individual cells by quantifying changes in mass versus time. Here, we use the breast cancer cell lines MCF-7, BT-474, and MDA-MB-231 to validate QPI as a multiparametric approach for determining response to single-agent therapies. Our method allows for rapid determination of drug sensitivity, cytotoxicity, heterogeneity, and time of response for up to 100,000 individual cells or small clusters in a single experiment. We find that QPI EC50 values are concordant with CellTiter-Glo (CTG), a gold standard metabolic endpoint assay. In addition, we apply multiparametric QPI to characterize cytostatic/cytotoxic and rapid/slow responses and track the emergence of resistant subpopulations. Thus, QPI reveals dynamic changes in response heterogeneity in addition to average population responses, a key advantage over endpoint viability or metabolic assays. Overall, multiparametric QPI reveals a rich picture of cell growth by capturing the dynamics of single-cell responses to candidate therapies.

• Authors: Edward R Polanco, Tarek E Moustafa, Andrew Butterfield, Sandra D Scherer, Emilio Cortes-Sanchez, Tyler Bodily, Benjamin T Spike, Bryan E Welm, Philip S Bernard, Thomas A Zangle
• Journal: Communications biology (Commun Biol) Vol. 5 Issue 1 Pg. 794 (08 08 2022) ISSN: 2399-3642 [Electronic] England
• PMID: 35941353 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
• Copyright: © 2022. The Author(s).

Chemical References

• Antineoplastic Agents

Topics

• Antineoplastic Agents (pharmacology, therapeutic use)
• Breast Neoplasms (drug therapy, metabolism)
• Cell Proliferation
• Drug Evaluation, Preclinical
• Early Detection of Cancer
• Female
• Humans